Strong sales growth and operation …

Appearance date: May 15, 2025

You can find the complete copy of the earnings call in the complete earnings call.

• Clice Inc (Nasdaq: PRPO) recorded an increase in sales of 1 and in front of 43% compared to the previous year and achieved $ 4.9 million, which indicates sustainable demand and growth in pathological services.

• Adjusted EBITDA improved by 92%with a loss of USD 108,000 compared to a loss of $ 1.4 million in the first quarter of the previous year, which shows improved operating efficiency.

• The test volume of the pathology department rose by 46% and sales rose by 53% compared to the previous year. 11 new doctors used their services, which reflects the strong market -loyal market.

• The gross margins for the Pathology department rose from 24% to 42% compared to the previous year, which is due to operational efficiency and scale.

• The PRPO (NASDAQ: PRPO) received the approval of Moppx for sequencing the next generation (NGS), which is expected to increase sales and the cash flow by approximately $ 0.25 million per quarter.

• Q1 2025 income decreased by 9.5% compared to the fourth quarter of 2024, which was due to typical seasonal patterns in the healthcare industry.

• The FDA judgment on laboratory development tests (LDTS) led to delays in the introduction of customers of customers in INC (NASDAQ: PRPO), which affects growth.

• The income of the product department was flat from the fourth quarter of 2024 to the first quarter of 2025, with the customer validation schedule largely outside the company's control.

• Due to a cyber attack on Change Healthcare, the company had a temporary disorder in the event of billing and collections in early 2024.

• Lectio Inc (Nasdaq: PRPO) still pursues the remaining 1 million US dollars from the Cares Act employee retention, which indicates potential delays when receiving these funds.

Q. A: Ilan Danieli, CEO: The decline is attributed to typical seasonal patterns in the healthcare industry, especially in diagnostics. The insurance plans will be reset on January 1 and the patients are moved to non -rotating tests until the costs are absorbed from the pocket, which affects test volumes and columns. This creates a temporary intake of income and cash flow that we expected. We already see a rebound in the second quarter and expect that we will return to a positive cash flow in the second quarter or second quarter of this year.

Q: How did the tests (LDTS) develop over Labor to the FDA decision over to your company? A: Ilan Danieli, CEO: The FDA decision about LDTS, which was lifted in March, had caused potential customers to delay the plans to bring our technology in the house. After the judgment has been canceled, some customers have resumed their interest and we expect constant growth of the product income that are Q2 in the second quarter.